Best deals to access real time data! |
|
CHART Trader
Monthly Subscription
for only
|
|
Canadian Level 1 + USA
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Hepion Pharmaceuticals Inc | HEPA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | High Price | Low Price | Open Price | Close Price | Last Traded  |
|
|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.0% | 2.86 | 0.00 | 0.00 | 0.00 | 2.86 | 19:00:00 |
| Bid Price | Ask Price | Spread | Spread % | News | |
|---|---|---|---|---|---|
| 2.81 | 3.01 | 0.20 | 6.64% | - | - |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 0.00 | USD |
Hepion Pharmaceuticals Financials
| Market Cap | Shares in Issue | Profit/Loss | Earnings Per Share (EPS) | PE Ratio | Float |
|---|---|---|---|---|---|
| $ 9.88M | 3.45M | -92.95 | - | 2.50M |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | - | - |
Hepion Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HEPA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.06 | 3.4099 | 2.80 | 3.08 | 213,255 | -0.20 | -6.54% |
| 1 Month | 4.24 | 5.79 | 2.80 | 3.52 | 2,167,241 | -1.38 | -32.55% |
| 3 Months | 2.43 | 5.79 | 2.03 | 3.45 | 767,502 | 0.43 | 17.7% |
| 6 Months | 3.11 | 5.79 | 2.0001 | 3.37 | 654,775 | -0.25 | -8.04% |
| 1 Year | 3.11 | 5.79 | 2.0001 | 3.37 | 654,775 | -0.25 | -8.04% |
| 3 Years | 3.11 | 5.79 | 2.0001 | 3.37 | 654,775 | -0.25 | -8.04% |
| 5 Years | 3.11 | 5.79 | 2.0001 | 3.37 | 654,775 | -0.25 | -8.04% |
Hepion Pharmaceuticals Description
| Hepion Pharmaceuticals Inc is a United States-based biopharmaceutical company engaged in the development of targeted pharmaceutical therapies for liver disease. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. The company's cyclophilin inhibitor, CRV431 targets multiple biochemical pathways involved in the progression of liver disease. |
